• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Cannabidiol plus conventional antiepileptics reduces drop seizure frequency in the Lennox-Gastaut syndrome

byIyas DaghlasandDayton McMillan
May 24, 2018
in Chronic Disease, Neurology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Amongst adults and children with the Lennox-Gastaut (LG) syndrome, addition of cannabidiol to a conventional antiepileptic regimen reduced drop seizure frequency compared to placebo treated patients.

2. The most common adverse events amongst patients treated with cannabidiol were diarrhea, somnolence, and decreased appetite. These effects were dose-dependent.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The LG syndrome is a developmental form of epilepsy. The syndrome is partly characterized by drop seizures, which can result in serious injury and significantly reduce patient quality of life. Cannabidiol has been shown to reduce the frequency of seizures in other settings, but its role in the treatment of LG syndrome remains unclear. Investigators sought to determine whether treatment with cannabidiol would significantly reduce rates of the primary outcome, the in frequency of drop seizures compared to baseline. In this multicenter randomized controlled trial, cannabidiol was found to significantly reduce the frequency of the primary outcome at fourteen weeks.

Strengths of this study include its randomized, multicenter study design, and recruitment of more patients than originally planned. Weaknesses include the use of percent change scores as the primary outcome and short follow-up time.

Click to read the study, published in NEJM

Relevant Reading: Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

RELATED REPORTS

Prenatal exposure to antiseizure medication associated with increased risk of autism and intellectual disability

New prognostication tool predicts neurological deficits and long-term survival in patients with status epilepticus

Treatment of rhythmic and periodic EEG patterns in comatose survivors of cardiac arrest

In-Depth [randomized controlled trial]: This was a phase III, multicenter, randomized controlled trial. The study population comprised patients aged 2-55 years with the LG syndrome, electroencephalogram findings characteristic of the disease, a history of drop seizures, and treatment with one to four antiepileptics (n=225). Nonpharmacological interventions were permitted so long as they were stable before and during the trial. Key exclusion criteria included use of cannabis in the previous three months or a history of substance or alcohol use. The interventions in the trial included either 20mg/kg/day (n=76) or 10mg/kg/day (n=73) of cannabidol, and placebo (n=76). The primary outcome consisted of the percent change in drop seizure frequency from baseline after a fourteen-week treatment period. Key secondary outcomes included comparison of the percentage of patients whose seizure frequency was cut in half, change in frequency of all seizure types, and a scale reflecting the caregiver’s impression of change.

Cannabidiol at both 20mg/kg/day and 10mg/kg/day dosing was superior to placebo (Difference in percent change20 vs. placebo=21.6%; 95% confidence interval [CI], 6.7 to 34.8; P=0.005; Difference in percent change10 vs. placebo=19.2%, 95% CI, 7.7 to 31.2, p = 0.002). All the aforementioned secondary outcomes were significantly improved in both treatment arms relative to placebo. Eighty-nine percent of adverse events were judged to be mild-moderate in severity, and were most commonly somnolence, decreased appetite, and diarrhea. The most common adverse event precipitating withdrawal from the trial was elevation in aminotransferases.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: epilepsylennox gastautseizures
Previous Post

Budesonide-formoterol as needed superior to terbutaline in mild asthma: The SYGMA trial

Next Post

2 Minute Medicine Rewind May 28, 2018

RelatedReports

Paternal factors associated with short interpregnancy interval
Neurology

Prenatal exposure to antiseizure medication associated with increased risk of autism and intellectual disability

June 3, 2022
Neurology

New prognostication tool predicts neurological deficits and long-term survival in patients with status epilepticus

April 15, 2022
Patient Basics: Electroencephalogram (EEG)
Cardiology

Treatment of rhythmic and periodic EEG patterns in comatose survivors of cardiac arrest

March 2, 2022
USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy
Neurology

Pregnant patients with epilepsy may benefit from increased doses of anticonvulsant medications

February 16, 2022
Next Post
Being overweight and obese associated with increased incidence of chronic kidney disease

2 Minute Medicine Rewind May 28, 2018

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Physicians report feeling moral distress over hospital policies that force inadequate care based on immigration status

Safety confirmation of propranolol use in treatment of infantile hemangiomas

Safety confirmation of propranolol use in treatment of infantile hemangiomas

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.